Literature DB >> 20189981

Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU.

Alain Ravaud, Christelle de la Fouchardière, Julien Asselineau, Jean-Pierre Delord, Christine Do Cao, Patricia Niccoli, Patrice Rodien, Marc Klein, Bogdan Catargi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20189981      PMCID： PMC3227944          DOI： 10.1634/theoncologist.2009-0303

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  2 in total

1.  The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent.

Authors:  E A GEHAN
Journal:  J Chronic Dis       Date:  1961-04

2.  A case of advanced medullary thyroid carcinoma successfully treated with sunitinib.

Authors:  Maria João Bugalho; Rita Domingues; Alexandra Borges
Journal:  Oncologist       Date:  2009-11-03
  2 in total
  11 in total

1.  A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.

Authors:  Keith C Bible; Vera J Suman; Julian R Molina; Robert C Smallridge; William J Maples; Michael E Menefee; Joseph Rubin; Nina Karlin; Kostandinos Sideras; John C Morris; Bryan McIver; Ian Hay; Vahab Fatourechi; Jill K Burton; Kevin P Webster; Carolyn Bieber; Anne M Traynor; Patrick J Flynn; Boon Cher Goh; Crescent R Isham; Pamela Harris; Charles Erlichman
Journal:  J Clin Endocrinol Metab       Date:  2014-02-25       Impact factor: 5.958

2.  Thyroid cancer: pathogenesis and targeted therapy.

Authors:  David A Liebner; Manisha H Shah
Journal:  Ther Adv Endocrinol Metab       Date:  2011-10       Impact factor: 3.565

Review 3.  Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions.

Authors:  R Dadu; M E Cabanillas
Journal:  Minerva Endocrinol       Date:  2012-12       Impact factor: 2.184

Review 4.  Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.

Authors:  Samuel A Wells; Furio Pacini; Bruce G Robinson; Massimo Santoro
Journal:  J Clin Endocrinol Metab       Date:  2013-06-06       Impact factor: 5.958

Review 5.  Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.

Authors:  Sujata Narayanan; A Dimitrios Colevas
Journal:  Curr Treat Options Oncol       Date:  2016-06

6.  Activity and safety of sunitinib in patients with advanced radioactive iodine-refractory differentiated thyroid carcinoma in clinical practice.

Authors:  Juan J Díez; Pedro Iglesias; Teresa Alonso; Enrique Grande
Journal:  Endocrine       Date:  2014-07-17       Impact factor: 3.633

Review 7.  Recent Updates on the Management of Medullary Thyroid Carcinoma.

Authors:  Bo Hyun Kim; In Joo Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2016-08-26

8.  Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma.

Authors:  Serena Giunti; Alessandro Antonelli; Andrea Amorosi; Libero Santarpia
Journal:  Int J Endocrinol       Date:  2013-02-21       Impact factor: 3.257

9.  Advanced medullary thyroid cancer: pathophysiology and management.

Authors:  Carla Vaz Ferreira; Débora Rodrigues Siqueira; Lucieli Ceolin; Ana Luiza Maia
Journal:  Cancer Manag Res       Date:  2013-05-08       Impact factor: 3.989

10.  An Integrated Data Driven Approach to Drug Repositioning Using Gene-Disease Associations.

Authors:  Joseph Mullen; Simon J Cockell; Peter Woollard; Anil Wipat
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.